CA2113683A1 - Traitement des maladies proliferatives, metastases et tumeurs pharmacoresistantes par des composes vanadate et derives ou analogues de vanadate - Google Patents
Traitement des maladies proliferatives, metastases et tumeurs pharmacoresistantes par des composes vanadate et derives ou analogues de vanadateInfo
- Publication number
- CA2113683A1 CA2113683A1 CA002113683A CA2113683A CA2113683A1 CA 2113683 A1 CA2113683 A1 CA 2113683A1 CA 002113683 A CA002113683 A CA 002113683A CA 2113683 A CA2113683 A CA 2113683A CA 2113683 A1 CA2113683 A1 CA 2113683A1
- Authority
- CA
- Canada
- Prior art keywords
- orthovanadate
- vanadate
- cells
- drug resistant
- vanadate compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002113683A CA2113683A1 (fr) | 1994-01-18 | 1994-01-18 | Traitement des maladies proliferatives, metastases et tumeurs pharmacoresistantes par des composes vanadate et derives ou analogues de vanadate |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002113683A CA2113683A1 (fr) | 1994-01-18 | 1994-01-18 | Traitement des maladies proliferatives, metastases et tumeurs pharmacoresistantes par des composes vanadate et derives ou analogues de vanadate |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2113683A1 true CA2113683A1 (fr) | 1995-07-19 |
Family
ID=4152759
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002113683A Abandoned CA2113683A1 (fr) | 1994-01-18 | 1994-01-18 | Traitement des maladies proliferatives, metastases et tumeurs pharmacoresistantes par des composes vanadate et derives ou analogues de vanadate |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2113683A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996011004A1 (fr) * | 1994-10-05 | 1996-04-18 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Agent pour le traitement de lesions malignes et pre-malignes positives de papillomavirus |
WO1997045105A1 (fr) * | 1996-05-24 | 1997-12-04 | Angiotech Pharmaceuticals, Inc. | Compositions et methodes pour traiter ou prevenir des maladies des voies corporelles |
WO1997047296A2 (fr) * | 1996-06-12 | 1997-12-18 | Mount Sinai Hospital Corporation | Compositions contenant des composes de vanadium utilisees dans le traitement des maladies proliferatives et des arthropathies |
-
1994
- 1994-01-18 CA CA002113683A patent/CA2113683A1/fr not_active Abandoned
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996011004A1 (fr) * | 1994-10-05 | 1996-04-18 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Agent pour le traitement de lesions malignes et pre-malignes positives de papillomavirus |
US6238659B1 (en) | 1994-10-05 | 2001-05-29 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Agent for treating papilloma virus-positive malignant and premalignant lesions |
WO1997045105A1 (fr) * | 1996-05-24 | 1997-12-04 | Angiotech Pharmaceuticals, Inc. | Compositions et methodes pour traiter ou prevenir des maladies des voies corporelles |
US6759431B2 (en) | 1996-05-24 | 2004-07-06 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating or preventing diseases of body passageways |
JP2004285074A (ja) * | 1996-05-24 | 2004-10-14 | Angiotech Pharmaceuticals Inc | 身体通路の疾患を処置または予防するための組成物および方法 |
WO1997047296A2 (fr) * | 1996-06-12 | 1997-12-18 | Mount Sinai Hospital Corporation | Compositions contenant des composes de vanadium utilisees dans le traitement des maladies proliferatives et des arthropathies |
WO1997047296A3 (fr) * | 1996-06-12 | 1998-03-05 | Mount Sinai Hospital Corp | Compositions contenant des composes de vanadium utilisees dans le traitement des maladies proliferatives et des arthropathies |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5871779A (en) | Treatment of arthropathies with vanadate compounds or analogues thereof | |
Coffey et al. | The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid | |
Witschi et al. | Modulation of lung tumor development in mice with the soybean-derived Bowman—Birk protease inhibitor | |
Zuckerbraun et al. | Carbon monoxide signals via inhibition of cytochrome c oxidase and generation of mitochondrial reactive oxygen species | |
Jiao et al. | Studies on anti-tumor and antimetastatic activities of fullerenol in a mouse breast cancer model | |
Stearns et al. | Taxol blocks processes essential for prostate tumor cell (PC-3 ML) invasion and metastases | |
Blask et al. | Physiological melatonin inhibition of human breast cancer cell growth in vitro: evidence for a glutathione-mediated pathway | |
US5843481A (en) | Treatment of proliferative disorders, metastasaes, and drug resistant tumors with vanadate compounds and derivatives or analogues thereof | |
Brandt et al. | Augmentation of intracellular iron using iron sucrose enhances the toxicity of pharmacological ascorbate in colon cancer cells | |
Karbownik et al. | Protective effects of melatonin against oxidation of guanine bases in DNA and decreased microsomal membrane fluidity in rat liver induced by whole body ionizing radiation | |
US6866864B2 (en) | Compositions and methods of use in the treatment of angiogenesis and vascular-related disorders | |
Satoh et al. | Modulation of both cisplatin nephrotoxicity and drug resistance in murine bladder tumor by controlling metallothionein synthesis | |
Liu et al. | Mediation of β-endorphin by myricetin to lower plasma glucose in streptozotocin-induced diabetic rats | |
Shahjahan et al. | Effect of Solanum trilobatum on the antioxidant status during diethyl nitrosamine induced and phenobarbital promoted hepatocarcinogenesis in rat | |
Bose et al. | Critical role of allyl groups and disulfide chain in induction of Pi class glutathione transferase in mouse tissues in vivo by diallyl disulfide, a naturally occurring chemopreventive agent in garlic | |
Kar et al. | The dual role of boron in vitro neurotoxication of glioblastoma cells via SEMA3F/NRP2 and ferroptosis signaling pathways | |
Salim | Removing oxygen-derived free radicals delays hepatic metastases and prolongs survival in colonic cancer: a study in the rat | |
US20040167217A1 (en) | Neuroprotective effects of polyphenolic compounds | |
CA2113683A1 (fr) | Traitement des maladies proliferatives, metastases et tumeurs pharmacoresistantes par des composes vanadate et derives ou analogues de vanadate | |
EP3989963A1 (fr) | Composés de carbocyanine pour cibler des mitochondries et éradiquer des cellules souches cancéreuses | |
Simpson et al. | β-Aminopropionitrile-induced aortic ruptures in turkeys: Inhibition by reserpine and enhancement by monoamine oxidase inhibitors | |
Churnratanakul et al. | Radiation and the small intestine | |
MXPA96002846A (en) | Vanadato compounds for the treatment of proliferative disorders, metastases, and farm-resistant tumors | |
Chang et al. | Effects of 1, 6-Bis [4-(4-amino-3-hydroxyphenoxy) phenyl] diamantane (DPD), a reactive oxygen species and apoptosis inducing agent, on human leukemia cells in vitro and in vivo | |
Teicher et al. | CAI: effects on cytotoxic therapies in vitro and in vivo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |